# MiR-205-5p and MiR-222-3p as Potential Biomarkers of Endometrial Cancer

**Authors:** Anna Bogaczyk, Natalia Potocka, Sylwia Paszek, Marzena Skrzypa, Alina Zuchowska, Michał Kośny, Marta Kluz-Barłowska, Andrzej Wróbel, Jan Wróbel, Izabela Zawlik, Tomasz Kluz

PMC · DOI: 10.3390/ijms26062615 · International Journal of Molecular Sciences · 2025-03-14

## TL;DR

This study explores miR-205-5p and miR-222-3p as potential biomarkers for endometrial cancer, comparing their expression in tissue and serum samples.

## Contribution

The study identifies miR-205-5p and miR-222-3p as potential non-invasive biomarkers for endometrial cancer detection.

## Key findings

- miR-205-5p showed increased expression in endometrial cancer tissue.
- miR-222-3p had decreased expression in both tissue and serum samples.
- miR-222-3p is a potential easily accessible diagnostic marker due to its decreased serum expression.

## Abstract

Endometrial cancer is the fourth most common cancer in women in Europe. Its carcinogenesis is a complex process and requires further research. In our study, we focus on finding new and easy-to-diagnose markers for detecting endometrial cancer. For this purpose, we compared the levels of miR-21-5p, miR-205-5p, and miR-222-3p in endometrial cancer tissues with the levels of these miRs in the serum of patients using the dPCR method. Our study is preliminary and consists of comparing the changes in miRNA expression in serum to the changes in miRNA in tissue of patients with endometrial cancer. The study included 18 patients with EC and 19 patients undergoing surgery for pelvic organ prolapse or uterine fibroids as a control group without neoplastic lesions. Endometrial tissue and serum were collected from all patients. The analyses showed an increased expression of miR-205-5p in endometrial cancer tissue and decreased expression of miR-222-3p in tissue and serum samples. These results suggest that miR-205-5p and miR-222-3p may be potential endometrial cancer biomarkers. Only miR-222-3p confirmed its decreased expression in serum, making it a potential and easily accessible marker in the diagnosis of endometrial cancer. This pilot study requires further investigation in a larger group of patients. Its advantages include the possibility of a comparison between miRNA expression in tissue and serum, as well as conducting the study using dPCR.

## Linked entities

- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** MIR215 (microRNA 215) [NCBI Gene 406997] {aka MIRN215, miRNA215, mir-215}
- **Diseases:** uterine fibroids (MESH:D007889), carcinogenesis (MESH:D063646), Endometrial Cancer (MESH:D016889), EC (MESH:D005955), pelvic organ prolapse (MESH:D056887), cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11941963/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11941963/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC11941963/full.md

---
Source: https://tomesphere.com/paper/PMC11941963